YWYuchao Wu

Yuchao Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuchao Wu has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • Li Zhu

    Department of Infectious Diseases and Hepatopathy, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

    3 shared publications
  • Ruojing Wang

    Department of Infectious Diseases and Hepatopathy, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

    3 shared publications
  • Yage Zhu

    Department of Infectious Diseases and Hepatopathy, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

    3 shared publications
  • Yali Feng

    Department of Infectious Diseases and Hepatopathy, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

    3 shared publications
  • Chengbin Zhu

    Department of Infectious Diseases and Hepatopathy, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

    2 shared publications
  • Fulian Zhao

    Department of Infectious Diseases and Hepatopathy, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

    2 shared publications

Latest Publications

  • Impact of year-to-year changes in skeletal muscle mass on the prediction of long-term survival in patients with liver cirrhosis

    by Fulian Zhao, Ruojing Wang, Chengbin Zhu, Chang Zhang, Tianzhi Ni, Qijuan Zang, Yali Feng, Mengmeng Zhang, Li Zhu, Yage Zhu, et al.


  • An RFH-NPT-based nomogram for predicting the long-term survival of liver cirrhosis patients: a multicenter study

    by Chengbin Zhu, Yuchao Wu, Fulian Zhao, Ruojing Wang, Qijuan Zang, Zhe Jiao, Yage Zhu, Taotao Yan, Juan Du, Li Zhu, et al.

    The Royal Free Hospital-Nutritional Prioritizing Tool (RFH-NPT) identifies nutritional risk in patients with liver disease, an important factor in cirrhosis outcomes. Recognizing the gap in existing prognostic models, which often overlook malnutrition, we developed and validated an RFH-NPT-based model for predicting outcomes of patients with cirrhosis. This study included inpatients with cirrhosis from a single center between February and July 2016 (training cohort) and patients from six other medical centers admitted between December 2011 and May 2022 (validation cohort). RFH-NPT assessment was conducted at admission, followed by a 5-year follow-up. A nomogram was created using prognostic variables from Cox modeling, best subset regression (BSR), and least absolute shrinkage and selection operator (LASSO) regression. Its performance was evaluated using various statistical methods and compared with that of existing models such as the Child‒Pugh, MELD, and MELD-Na. A total of 152 patients were included in the training cohort. The nutritional risk was significantly greater in nonsurvivors (81.1%) than in survivors (46.5%). The nomogram showed better accuracy in predicting 1-, 3-, and 5-year survival than traditional methods. The nomogram's effectiveness was confirmed in the validation cohort of 320 patients. This study re-emphasizes the critical role of malnutrition in patients with liver cirrhosis and establishes an effective RFH-NPT-based model for outcome prediction. This study is registered at Clinicaltrials.gov (NCT05513651).


  • Open Access

    Royal Free Hospital-Nutritional Prioritizing Tool improves the prediction of malnutrition risk outcomes in liver cirrhosis patients compared with Nutritional Risk Screening 2002

    by Yuchao Wu, Yage Zhu, Yali Feng, Ruojing Wang, Naijuan Yao, Mengmeng Zhang, Xiaohui Liu, Huan Liu, Lei Shi, Li Zhu, et al.

    The European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines recommend the Royal Free Hospital-Nutritional Prioritizing Tool (RFH-NPT) to identify malnutrition risk in patients with liver disease. However, little is known about the application of the RFH-NPT to screen for the risk of malnutrition in China, where patients primarily suffer from hepatitis virus-related cirrhosis. A total of 155 cirrhosis patients without liver cancer or uncontrolled co-morbid illness were enrolled in this prospective study. We administered the Nutritional Risk Screening 2002 (NRS-2002), RFH-NPT, Malnutrition Universal Screening Tool (MUST) and Liver Disease Undernutrition Screening Tool (LDUST) to the patients within 24 h after admission and performed follow-up observations for 1·5 years. The RFH-NPT and NRS-2002 had higher sensitivities (64·8 and 52·4 %) and specificities (60 and 70 %) than the other tools with regard to screening for malnutrition risk in cirrhotic patients. The prevalence of nutritional risk was higher under the use of the RFH-NPT against the NRS-2002 (63 v. 51 %). The RFH-NPT tended more easily to detect malnutrition risk in patients with advanced Child–Pugh classes (B and C) and lower Model for End-stage Liver Disease scores (<15) compared with NRS-2002. RFH-NPT score was an independent predictive factor for mortality. Patients identified as being at high malnutrition risk with the RFH-NPT had a higher mortality rate than those at low risk; the same result was not obtained with the NRS-2002. Therefore, we suggest that using the RFH-NPT improves the ability of clinicians to predict malnutrition risk in patients with cirrhosis primarily caused by hepatitis virus infection at an earlier stage.


  • Open Access

    Efficacy and safety of antiviral therapy for HBV in different trimesters of pregnancy: systematic review and network meta-analysis

    by Yuchao Wu, Jinfeng Liu, Yali Feng, Shan Fu, Fanpu Ji, Long Ge, Naijuan Yao, Xufei Luo, Yingren Zhao, Yaolong Chen, et al.

    Background: Several antiviral agents licenced for blocking mother-to-child transmission (MTCT) of HBV, but their relative efficacy beginning fromdifferent trimestershas scarce been evaluated. We aimed to conduct a network meta-analysis to statistically differ the efficacy and safety of each antiviral agents initiating on different timings in preventing mother-to-infant transmission of HBV.Methods: Studies were included from PubMed, EMBASE, Web of Science, and Cochrane databases through July 1, 2019. Eligible studies recruited randomized controlled trials and nonrandomized studies reporting about infant or/and maternal efficacy and safety outcomes and were screened by two investigators independently. Extracted data were analyzed by pair-wised and network meta-analysis, respectively.Results: 3 Randomized and 32 nonrandomized studies enrolling 6738 pregnant female were included. Using network analysis, any antiviral agent interrupted HBV vertical transmission much more effectively than placebo. No agent showed significant efficacy different from others, but a strong trend toward significance was found in telbivudine and tenofovir, of which had the highest probability of being ranked the first- or second-best treatment for reducing MTCT of HBV. The treatment applied in the first and second trimester had a similar efficacy in preventing MTCT. Compared with the initiation during the third trimester, lower rate of MTCT was revealed when antiviral therapy was administrated before third trimester, (RR = 0.045, 95% CI 0.0053 to 0.20); a similar effect at delivery on suppressing maternal HBV DNA level and converting serum HBeAg were achieved if the timing of antiviral treatment started prior, but an obvious improvement of normalizing ALT flare was calculated out; no statistically differences among maternal and fetal safety outcomes were found if mothers received antiviral agents before pregnant 28 weeks.Conclusion: This network meta-analysis recommended the earlier use of telbivudine or tenofovir, tends to be better to prevent MTCT of HBV in pregnancy with no increased adverse maternal or fetal outcomes.